1. Home
  2. MLEC vs KPRX Comparison

MLEC vs KPRX Comparison

Compare MLEC & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLEC
  • KPRX
  • Stock Information
  • Founded
  • MLEC 2008
  • KPRX 1998
  • Country
  • MLEC Cayman Islands
  • KPRX United States
  • Employees
  • MLEC N/A
  • KPRX N/A
  • Industry
  • MLEC Blank Checks
  • KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • MLEC Finance
  • KPRX Health Care
  • Exchange
  • MLEC Nasdaq
  • KPRX Nasdaq
  • Market Cap
  • MLEC 10.1M
  • KPRX 9.2M
  • IPO Year
  • MLEC N/A
  • KPRX N/A
  • Fundamental
  • Price
  • MLEC $0.62
  • KPRX $2.53
  • Analyst Decision
  • MLEC
  • KPRX Strong Buy
  • Analyst Count
  • MLEC 0
  • KPRX 1
  • Target Price
  • MLEC N/A
  • KPRX $10.00
  • AVG Volume (30 Days)
  • MLEC 295.3K
  • KPRX 49.9K
  • Earning Date
  • MLEC 11-11-2025
  • KPRX 11-07-2025
  • Dividend Yield
  • MLEC N/A
  • KPRX N/A
  • EPS Growth
  • MLEC N/A
  • KPRX N/A
  • EPS
  • MLEC N/A
  • KPRX N/A
  • Revenue
  • MLEC N/A
  • KPRX N/A
  • Revenue This Year
  • MLEC $20.42
  • KPRX N/A
  • Revenue Next Year
  • MLEC $30.00
  • KPRX N/A
  • P/E Ratio
  • MLEC N/A
  • KPRX N/A
  • Revenue Growth
  • MLEC 170.36
  • KPRX N/A
  • 52 Week Low
  • MLEC $0.61
  • KPRX $2.21
  • 52 Week High
  • MLEC $10.47
  • KPRX $4.18
  • Technical
  • Relative Strength Index (RSI)
  • MLEC 21.12
  • KPRX 40.93
  • Support Level
  • MLEC $0.63
  • KPRX $2.21
  • Resistance Level
  • MLEC $0.72
  • KPRX $2.68
  • Average True Range (ATR)
  • MLEC 0.07
  • KPRX 0.15
  • MACD
  • MLEC 0.03
  • KPRX -0.02
  • Stochastic Oscillator
  • MLEC 4.28
  • KPRX 38.28

About MLEC Moolec Science SA

Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's revenues arise from operations in Argentina.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: